Heart rate control with if inhibitor, ivabradine, in Japanese patients with chronic heart failure–A randomized, double-blind, placebo-controlled phase II study–

The study investigators

研究成果: ジャーナルへの寄稿記事

12 引用 (Scopus)


Background: Elevated heart rate (HR) is an independent risk factor for cardiovascular outcomes in various cardiac diseases, including heart failure (HF). Methods and Results: Randomized placebo-controlled study was conducted to evaluate the effects of ivabradine, an If inhibitor, on the resting HR in 126 Japanese symptomatic HF patients with left ventricular ejection fraction ≤35%, resting HR ≥75 beats/min in sinus rhythm, and stable, optimal background treatment. Patients were randomly allocated into 3 groups: placebo; starting dose of ivabradine 2.5 mg twice daily (BID; 2.5 mg group 5 mg BID group. The dose was increased up to 7.5 mg BID according to dose-adjustment criteria. After the 6-week treatment, the reductions in resting HR were significant in both the 2.5-mg (16.6±8.1 beats/min) and 5-mg (16.4±9.6 beats/min) groups (P<0.0001 for both groups) compared with placebo (1.7±8.7 beats/min). The most frequent side effect of ivabradine was phosphenes, but all were mild. Treatment was discontinued in 1 patient due to HF in the 5 mg group. Conclusions: Ivabradine starting at 2.5 or 5 mg BID effectively reduced resting HR in Japanese HF patients. Ivabradine at the starting dose of 2.5 mg BID could be safer than 5 mg BID.

ジャーナルCirculation Journal
出版物ステータス出版済み - 2 25 2016


All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine